Nepafenak w praktyce lekarza okulisty – co decyduje o jego skuteczności i bezpieczeństwie stosowania?

• Authors: Jarosław Woroń

Title variants

EN

Nepafenac in the practice of an ophthalmologist – what determines its effectiveness and safety of use?

• Languages of publication: PL

Abstracts

PL

W terapii zapalnych chorób narządu wzroku okulista staje niejednokrotnie przed niełatwym wyborem strategii leczenia farmakologicznego. Warto pamiętać, że dostępne leki okulistyczne mogą zasadniczo różnić się między sobą, stąd tak istotne jest uwzględnienie profilu farmakokinetyczno-farmakodynamicznego stosowanych leków. Odmienne mechanizmy działania, a także różna tolerancja miejscowo stosowanych leków mogą wpływać zarówno na efektywność, jak i bezpieczeństwo leczenia.

EN

In the treatment of inflammatory eye diseases, the ophthalmologist often has to face a difficult choice of pharmacological treatment strategies. It is worth remembering that the available ophthalmic drugs may differ substantially from one another, hence it is important to take into account the pharmacokinetic- pharmacodynamic profile of the drugs used. Different mechanisms of action as well as different tolerance of topically applied drugs can affect both the effectiveness and safety of the treatment.

Keywords

EN

leczenie stanów zapalnych; nepafenak; zaćma

Discipline

• PHARMACOLOGY: PHARMACOLOGY

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2019
• Volume: 6
• Issue: 1
• Pages: 39-42

Contributors

author

Jarosław Woroń

• Zakład Farmakologii Klinicznej, Katedra Farmakologii, Wydział Lekarski, Uniwersytet Jagielloński – Collegium Medicum

References

• 1. Chin MS, Nagineni CN, Hooper LC, et al. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2001; 42: 2338-2346.
• 2. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010; 55: 108-133.
• 3. Jones B, Neville MW. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery. Ann Pharmacother 2013; 47: 892-896.
• 4. Guo S, Patel S, Baumrind B, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol 2015; 60: 123-137.
• 5. O’Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin 2005; 21: 1131-1137.
• 6. Schoenberger SD, Miller DM, Petersen MR, et al. Nepafenac for epiretinal membrane surgery. Ophthalmology 2011; 118: 1482.e1- -1482.e3.
• 7. Naithani P, Puranik S, Vashisht N, et al. Role of topical nepafenac in prevention and treatment of macular edema after vitreoretinal surgery. Retina 2012; 32: 250-255.
• 8. Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma- -induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000; 24: 357-370.
• 9. Colin J, Paquette B. Comparison of the analgesic efficacy of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial. Clin Ther 2006; 28: 527-536.
• 10. Durrie DS, Kennard MG, Boghossian AJ. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). Adv Ther 2007; 24(6): 1278-1285.
• 11. Gomi F, Sawa M, Tsujikawa M, Nishida K. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina 2012; 32: 1804-1810.
• 12. Sahoo S, Baruna A, Myint KT, et al. Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema (review). The Cochrane Library 2015; 2: 1-17.
• 13. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma- -induced ocular inflammation. II. In vitro band permeation of external ocular barriers. Inflammation 2000; 24(4): 371-384.
• 14. Cardascia N, Palmisano C, Centoducati T, et al. Topical nonsteroidal anti-inflammatory drugs as adjuvant therapy in the prevention of macular edema after cataract surgery. Int Ophthalmol 2017; 37: 1127-1131.

• Document Type: article